The politics and policies of high drug prices have been swirling around for years. But recently, attention has shifted to PBMs, which used to reside in an obscure corner of the U.S. healthcare system. At the federal level, Federal Trade Commission has launched a study of the industry and possible anticompetitive practices. A bipartisan bill has been introduced in the Senate that its sponsors say would force needed transparency and fairness on PBMs.
top of page
bottom of page